Chiron Corporation (Nasdaq:CHIR) today announced that the staff of the Securities and Exchange Commission (SEC) has decided to terminate its investigation of whether Chiron violated any federal securities laws in connection with the previous suspension by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of Chiron's license to manufacture FLUVIRIN(R) influenza virus vaccine and has ended its inquiry into the company's restatement of financial results for the second and third quarters of 2004. Chiron has been informed that no enforcement action has been recommended against the company in connection with these matters. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com.
Chiron (NASDAQ:CHIR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Chiron 차트를 더 보려면 여기를 클릭.
Chiron (NASDAQ:CHIR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Chiron 차트를 더 보려면 여기를 클릭.